Affordable Access

Access to the full text

Elite controllers: A heterogeneous group of HIV-infected patients

Authors
  • Navarrete-Muñoz, María A.1, 2, 3
  • Restrepo, Clara1, 2
  • Benito, José M.1, 2
  • Rallón, Norma1, 2
  • 1 Instituto De Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma De Madrid (IIS-FJD, UAM), Spain , (Spain)
  • 2 Hospital Universitario Rey Juan Carlos, Spain , (Spain)
  • 3 Biotechvana, Scientific Park, Spain , (Spain)
Type
Published Article
Journal
Virulence
Publisher
Landes Bioscience
Publication Date
Jul 22, 2020
Volume
11
Issue
1
Pages
889–897
Identifiers
DOI: 10.1080/21505594.2020.1788887
PMID: 32698654
PMCID: PMC7549999
Source
PubMed Central
Keywords
License
Green

Abstract

The exceptional group of ECs has been of great help, and will continue to provide invaluable insight with regard to reach a potential functional cure of HIV. However, there is no consensus on the immune correlates associated to this EC phenotype which preclude reaching a potential functional cure of HIV. The existing literature studying this population of individuals has indeed revealed that they are a very heterogeneous group regarding virological, immunological, and even clinical characteristics, and that among ECs only a very small proportion are homogeneous in terms of maintaining virological and immunological control in the long term (the so-called long-term elite controllers, LTECs). Thus, it is of pivotal relevance to identify the LTECs subjects and use them as the right model to redefine immune correlates of a truly functional cure. This review summarizes the evidence of the heterogeneity of HIV elite controllers (ECs) subjects in terms of virological, immunological and clinical outcomes, and the implications of this phenomenon to adequately consider this EC phenotype as the right model of a functional cure.

Report this publication

Statistics

Seen <100 times